Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Pancreatic cancer is a tough disease to catch early because it doesn’t always cause clear symptoms right away. Still, noticing changes in your body can…
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they…
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…
Innovent Biologics will license IBI3009, its investigational DLL3-targeted antibody–drug conjugate (ADC) for small cell lung cancer (SCLC), to Roche for $80 million upfront and payments…
Many patients with multiple myeloma experience persistent pain and use opioids to manage that pain even after they achieve remission, a survey suggests.
